Spire Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Spire Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38K	Hold	77	–	–	﹤0.01%	2079
2026 Q1	$1.68K	Hold	77	–	–	﹤0.01%	2068
2025 Q4	$1.66K	Buy	+77	New	+$1.62K	﹤0.01%	2132
2025 Q2	–	Sell	-8	Closed	-$511	–	2554
2025 Q1	$511	Sell	8 -1	-11%	-$105	﹤0.01%	2463
2024 Q4	$1.09K	Hold	9	–	–	﹤0.01%	2351
2024 Q3	$1.12K	Hold	9	–	–	﹤0.01%	2081
2024 Q2	$1.42K	Buy	9 +3	+50%	+$385	﹤0.01%	2067
2024 Q1	$777	Hold	6	–	–	﹤0.01%	2244
2023 Q4	$694	Hold	6	–	–	﹤0.01%	2319
2023 Q3	$727	Sell	6 -220	-97%	-$24.9K	﹤0.01%	2307
2023 Q2	$25.9K	Buy	226 +220	+3,667%	+$28.4K	﹤0.01%	1477
2023 Q1	$827	Buy	+6	New	+$778	﹤0.01%	2409
2022 Q2	–	Sell	-20	Closed	-$2K	–	2822
2022 Q1	$2K	Sell	20 -3,825	-99%	-$293K	﹤0.01%	2419
2021 Q4	$346K	Buy	3,845 +3,825	+19,125%	+$327K	0.01%	845
2021 Q3	$2K	Hold	20	–	–	﹤0.01%	2485
2021 Q2	$2K	Sell	20 -4,025	-100%	-$305K	﹤0.01%	2500
2021 Q1	$302K	Buy	+4,045	New	+$373K	0.01%	864

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Spire Wealth Management's SRPT Position: Q2 2026 in Review

Spire Wealth Management held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 77 shares worth $1.38K. The position accounts for ﹤0.01% of the portfolio, ranked #2079.

Spire Wealth Management first reported a position in SRPT in Q1 2021 and has held it in 17 quarters since. The position peaked at $346K in Q4 2021. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Spire Wealth Management held 77 shares of Sarepta Therapeutics worth $1.38K as of Q2 2026.
Spire Wealth Management left its Sarepta Therapeutics share count unchanged in Q2 2026.
Sarepta Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #2079 holding.
Spire Wealth Management first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 17 quarters since.
Spire Wealth Management's Sarepta Therapeutics position peaked at $346K in Q4 2021.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.